Unknown

Dataset Information

0

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).


ABSTRACT: OBJECTIVE:The Tysabri Observational Programme (TOP), which began >10 years ago, is an open-label, multinational, prospective observational study evaluating the long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients. METHODS:These data provide a 10-year interim analysis of safety and effectiveness in TOP. Annualised relapse rates (ARRs) and disability progression/improvement were analysed using the Poisson model and the Kaplan-Meier method, respectively. Analyses included patients on natalizumab and those who discontinued natalizumab but remained in TOP. RESULTS:As of November 2017, TOP included 6148 patients. Overall, 829 patients (13.5%) experienced ?1 serious adverse event (SAE), with infection the most common (4.1%). Fifty-three patients (0.9%) had confirmed progressive multifocal leukoencephalopathy. SAE data were consistent with natalizumab's known safety profile; no new safety signals were identified. A total of 3210 patients (52.2%) discontinued natalizumab; 2117 (34.4%) withdrew from TOP. Median time on natalizumab was 3.3 (range 0-11.6) years; median follow-up time was 5.2 (range 0-10.8) years. The on-natalizumab ARR was 0.15, a 92.5% reduction from the year before initiation. Ten-year cumulative probabilities of disability worsening and improvement were 27.8% and 33.1%, respectively. On-natalizumab ARRs were similar between patients who discontinued or remained on natalizumab, suggesting limited attrition bias. CONCLUSIONS:Since the TOP 5-year interim analysis (December 2012), cohort size (6148 vs 4821), median exposure (3.3 vs 1.8 years) and median follow-up time (62 vs 26 months) have increased. This 10-year interim analysis further supports the robust real-world effectiveness and well-established safety profile of natalizumab. TRIAL REGISTRATION NUMBER:NCT00493298.

SUBMITTER: Butzkueven H 

PROVIDER: S-EPMC7279201 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).

Butzkueven Helmut H   Kappos Ludwig L   Wiendl Heinz H   Trojano Maria M   Spelman Tim T   Chang Ih I   Kasliwal Rachna R   Jaitly Seema S   Campbell Nolan N   Ho Pei-Ran PR   Licata Stephanie S  

Journal of neurology, neurosurgery, and psychiatry 20200331 6


<h4>Objective</h4>The Tysabri Observational Programme (TOP), which began >10 years ago, is an open-label, multinational, prospective observational study evaluating the long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients.<h4>Methods</h4>These data provide a 10-year interim analysis of safety and effectiveness in TOP. Annualised relapse rates (ARRs) and disability progression/improvement were analysed using the Poisson model and the Kaplan-Meier met  ...[more]

Similar Datasets

| S-EPMC10043118 | biostudies-literature
| S-EPMC4967609 | biostudies-literature
| S-EPMC10630909 | biostudies-literature
| S-EPMC6812766 | biostudies-literature
| S-EPMC6835923 | biostudies-literature
| S-EPMC8481711 | biostudies-literature
| S-EPMC9912999 | biostudies-literature
| S-EPMC8620632 | biostudies-literature
| S-EPMC8478746 | biostudies-literature
| S-EPMC8497120 | biostudies-literature